Avadel Pharma (NASDAQ: AVDL) reported Q4 EPS of ($0.32), $0.04 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $19.45 million versus the consensus estimate of $18.21 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.